Level Bio AB (publ) (NGM:LEVBIO)
Sweden · Delayed Price · Currency is SEK 0.2760
-0.0100 (-3.50%)
At close: May 5, 2026
Level Bio AB Earnings Call Transcripts
Fiscal Year 2025
-
Q3 net sales grew 5% year-over-year, with a 30% increase for the first nine months. Gross margin improved to 57%, and cash flow turned positive. The group is focused on organic growth, cost control, and expanding its product portfolio in precision diagnostics.
-
Platform enhancements and new business initiatives are underway, including a Q4 pilot and lab partnerships. Key metrics such as 70% and 46% were mentioned, with ongoing capital allocation and business development efforts.
-
Nordic markets saw 44% year-over-year growth, driven by rebranding and technology initiatives. Over 50% of targets were met, with notable progress in cost management and global platform expansion.